Publications by authors named "Heidy Russell"
Article Synopsis
- - A study was conducted to assess the safety and effectiveness of bexagliflozin, a medication for type 2 diabetes, at three different doses (5, 10, and 20 mg) over 12 weeks, comparing it to a placebo in patients who had minimal previous medication exposure.
- - Results showed that all doses of bexagliflozin significantly reduced HbA1c levels, with the 20 mg dose showing the most substantial decrease, along with improvements in fasting plasma glucose and body mass.
- - The medication had a similar incidence of adverse effects as the placebo, indicating it is generally safe; further research is recommended to explore its long-term effects for managing type 2 diabetes.
Purpose: In Phase III trials, delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated significant efficacy and an acceptable safety profile in patients with relapsing-remitting multiple sclerosis. The purpose of the present study was to examine 2 potential mitigation strategies for flushing and gastrointestinal (GI) events associated with DMF treatment: aspirin (ASA) 325 mg pretreatment for flushing, and slow dose titration of DMF for flushing and GI events.
Methods: The 8-week study included 173 healthy volunteers randomized to 4 groups; 172 underwent dosing.
Background: Delayed-release dimethyl fumarate (DR-DMF) has cytoprotective and antiinflammatory properties and has recently been approved in the United States as an oral treatment for relapsing forms of multiple sclerosis. The most common adverse events associated with DR-DMF are flushing and gastrointestinal (GI) events, the incidences of which diminish over time.
Objective: The purpose of this study was to evaluate the tolerability and pharmacokinetic (PK) profile of DR-DMF with or without concomitant acetylsalicylic acid (aspirin), a cyclooxygenase inhibitor.
This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). Sustained improvements in AM and PM peak expiratory flow (PEF) were observed in the zileuton CR group compared to placebo. The adverse event profile was similar in the two treatment groups.
View Article and Find Full Text PDF